European Medicines Regulatory Network (EMRN) workshop on Geographic Atrophy endpoints, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, 29 April 2026

Notices and alerts per role - CTIS Training Programme - Module 07

Avtozma

New product information wording - Extracts from PRAC recommendations on signals adopted at the 9-12 March 2026 PRAC

PRAC recommendations on signals adopted at the 9-12 March 2026 PRAC meeting

List of signals discussed at PRAC since September 2012

Human medicines European public assessment report (EPAR): Keppra, levetiracetam, Date of authorisation: 29/09/2000, Revision: 58, Status: Authorised

Human medicines European public assessment report (EPAR): Ryzneuta, efbemalenograstim alfa, Date of authorisation: 21/03/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Ilumira, lutetium (177Lu) chloride, Date of authorisation: 26/03/2026, Status: Authorised

Human medicines European public assessment report (EPAR): RoActemra, tocilizumab, Date of authorisation: 16/01/2009, Revision: 49, Status: Authorised